Balaxi Pharmaceuticals reports NIL physical share transfers in May 2026

Balaxi Pharmaceuticals reported zero activity regarding the re-lodgement of transfer requests for physical shares during May 2026. This disclosure was made in compliance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated 30 January 2026, which established a special window for such requests. The company filed the report with the National Stock Exchange of India on 06 June 2026.

The Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, provided the status update to the company's compliance officer. The report confirms that no shareholders sought to transfer physical shares through the special mechanism during the specified period. Consequently, there were no approvals, rejections, or processing times recorded for the month.

Status of Physical Share Transfer Requests

The data provided by Aarthi Consultants Private Limited covers the period ended May 2026. The table below details the processing statistics for the re-lodgement of transfer requests under the SEBI mandate.

No. of requests received during the month	No. of requests processed during the month	No. of requests approved during the month	No. of requests rejected during the month	Average time taken for processing of requests (in days)
NIL	NIL	NIL	NIL	NA

The filing was signed by Aman Purohit, Company Secretary & Compliance Officer of Balaxi Pharmaceuticals . The complete report is available on the company's official website. Aarthi Consultants Private Limited serves as the Category I Registrar and Share Transfer Agent for the entity.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.68%	-7.30%	-18.68%	-30.80%	-58.07%	-81.37%

Balaxi Pharmaceuticals Limited reported a net profit of ₹1.42 crore for the financial year ended March 31, 2026, a sharp decline of 94.3% compared to ₹25.07 crore in the previous year. Consolidated revenue from operations for the year fell 7.7% to ₹270.17 crore from ₹292.56 crore in FY25. The company attributed the revenue decline to an extended working capital cycle in its institutional business, particularly in Angola, while its Latin America (LATAM) segment delivered strong growth with revenue increasing 11% year-on-year to ₹111.29 crore.

Financial Performance

The Board of Directors approved the audited consolidated financial results for the fourth quarter and financial year ended March 31, 2026. Despite the lower revenues, gross profit margins improved to 44.2% in FY26 from 43.4% in the previous year, reflecting an improved business mix and disciplined product selection. The company’s EBITDA for the year stood at ₹11.35 crore, down 66.1% from ₹33.50 crore in FY25.

Particulars (INR Crore)	FY26	FY25	YoY
Revenue	270.17	292.56	(7.7%)
Gross Profit	119.30	126.86	(6.0%)
Gross Margin %	44.2%	43.4%	+80 bps
EBITDA	11.35	33.50	(66.1%)
Profit After Tax	1.42	25.07	(94.3%)

For the quarter ended March 31, 2026, the company recorded a net profit of ₹0.61 crore, a decrease of 92.9% from ₹8.64 crore in the corresponding quarter of the previous year. Quarterly revenue declined 7.3% to ₹70.71 crore.

Operational Updates

During the year, the company secured 49 new product registrations across Latin America, bringing its total portfolio to 964 registered products. A major milestone was achieved with the receipt of the Manufacturing Licence for the company’s first pharmaceutical formulation facility at Jadcherla, Hyderabad. The facility, focusing on General Oral Solid Dosage (OSD) formulations, is now commissioned and targets demand for high-quality products in Latin American markets. This move supports the company’s transition from an “Asset Light” to an “Asset Right” model, aiming for backward integration and improved profit margins.

Strategic Outlook

Looking ahead, the company remains focused on scaling its institutional business, expanding its product portfolio, and operationalising the new formulation facility. Management has also initiated the process of discontinuing its ancillary Building Hardware business to sharpen its focus on pharmaceuticals and improve working capital efficiency.